Alerte De Sécurité sur Alere INRatio2 PT/INR Professional Test Strips

Selon Department of Health, ce/cet/cette alerte de sécurité concerne un dispositif en/au/aux/à Hong Kong qui a été fabriqué par Alere.

Qu'est-ce que c'est?

Les alertes fournissent des informations importantes et des recommandations concernant les dispositifs médicaux. Le fait qu'une alerte soit émise ne signifie pas nécessairement qu'un dispositif soit dangereux. Les alertes de sécurité, qui sont envoyées tant aux travailleurs du secteur médical qu'aux utilisateurs de ces dispositifs, peuvent inclure des rappels. Elles peuvent être rédigées par des fabricants mais aussi par des autorités en charge de la santé.

En savoir plus sur les données ici
  • Type d'événement
    Safety alert
  • Date
    2014-05-07
  • Date de publication de l'événement
    2014-05-07
  • Pays de l'événement
  • Source de l'événement
    DH
  • URL de la source de l'événement
  • Notes / Alertes
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • Notes supplémentaires dans les données
    Medical Device Safety Alert
  • Cause
    Medical device safety alert: alere inratio2 pt/inr professional test strips the u.S. food and drug administration (fda) and the australia therapeutic goods administration (tga) posted a medical device safety alert concerning inratio2 pt/inr professional test strips, manufactured by alere. there were complaints of patients who had a therapeutic or near therapeutic inr with the alere inratio2 pt/inr professional test strip but a significantly higher inr (outside of therapeutic range) when performed by a central laboratory. the manufacturer has received nine serious adverse event reports, three of which described bleeding associated with patient deaths. the reason for the adverse event reports was significantly different test results between the alere inratio2 pt/inr professional test strip and the local laboratory plasma inr test. the alere inratio2 pt/inr professional test strip results were between 3.1 – 12.2 inr units lower than the laboratory result. there may be risk of inaccurately low inr result. the manufacturer has advised users to immediately stop using the alere inratio2 pt/inr professional test strips. it has also advised users to use an alternative method to perform pt/inr testing, such as a plasma-based laboratory inr test, an alternative alere product, or an alternative point-of-care monitoring system from a different manufacturer. the manufacturer is notifying healthcare providers of an update to the limitations of use for the inratio 2 pt/inr tests strips. consumers are being provided with a safety alert notification advising of potential issues with the accuracy of the device and the correct clinical practice with regard to medication dosing. furthermore, the manufacturer will transition customers from the current alere inratio2 pt/inr professional test strip to the alere inratio pt/inr test strip (pn 100139). professional test strip to the alere inratio pt/inr test strip (pn 100139). for details, please refer to: the fda website http://www.Fda.Gov/safety/recalls/ucm396219.Htm and the tga website http://www.Tga.Gov.Au/sara/arn-detail.Aspx?k=rc-2014-rn-00471-1 if you are in possession of the product, please contact your supplier for necessary actions. posted on 7 may 2014.

Device

  • Modèle / numéro de série
  • Classification du dispositif
  • Description du dispositif
    Medical Device Safety Alert: Alere INRatio2 PT/INR Professional Test Strips
  • Manufacturer

Manufacturer

  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DH